Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake
The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Abstract
Obesity is a growing epidemic, and current medical therapies have proven inadequate. Endogenous satiety hormones provide an attractive target for the development of drugs that aim to cause effective weight loss with minimal side effects. Both glucagon and GLP-1 reduce appetite and cause weight loss. Additionally, glucagon increases energy expenditure. We hypothesized that the combination of both peptides, administered at doses that are individually subanorectic, would reduce appetite, while GLP-1 would protect against the hyperglycemic effect of glucagon. In this double-blind crossover study, subanorectic doses of each peptide alone, both peptides in combination, or placebo was infused into 13 human volunteers for 120 min. An ad libitum meal was provided after 90 min, and calorie intake determined. Resting energy expenditure was measured by indirect calorimetry at baseline and during infusion. Glucagon or GLP-1, given individually at subanorectic doses, did not significantly reduce food intake. Coinfusion at the same doses led to a significant reduction in food intake of 13%. Furthermore, the addition of GLP-1 protected against glucagon-induced hyperglycemia, and an increase in energy expenditure of 53 kcal/day was seen on coinfusion. These observations support the concept of GLP-1 and glucagon dual agonism as a possible treatment for obesity and diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · PubMed · Cited by 13,173
Obesity : Preventing and managing the global epidemic
Akram, D. S., Astrup, A. V., Atinmo, T., Boissin, J.-L., Bray, G. A., Carroll, K. N., Chitson, P., Chen, C., Dietz, W. H., Hill, J. O., et al. (2000) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 12,945
New methods for calculating metabolic rate with special reference to protein metabolism
Weir, J. B. D. V. (1949) · The Journal of Physiology · doi:10.1113/jphysiol.1949.sp004363 · Cited by 5,603 · cited 1×
“Resting energy expenditure (REE), respiratory quotient (RQ), and carbohydrate and fat oxidation rates were calculated from the VO2 and VCO2 measured at 1-min intervals, and adjusted for urinary nitrogen excretion (27,28).”
MethodThe thrifty phenotype hypothesis
Hales, C. N., & Barker, D. J. P. (2001) · British Medical Bulletin · doi:10.1093/bmb/60.1.5 · Cited by 2,738 · cited 1×
“The current study was therefore designed to demonstrate the acute effects of intravenous infusion of GLP-1 and glucagon when given at low doses, both alone and in combination, on food intake (22), glucose homeostasis, and energy expenditure in humans.”
BackgroundCalculation of substrate oxidation rates in vivo from gaseous exchange.
Frayn, K. N. (1983) · Journal of Applied Physiology · doi:10.1152/jappl.1983.55.2.628 · Cited by 2,365 · cited 1×
“Resting energy expenditure (REE), respiratory quotient (RQ), and carbohydrate and fat oxidation rates were calculated from the VO2 and VCO2 measured at 1-min intervals, and adjusted for urinary nitrogen excretion (27,28).”
MethodChanges in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 1×
“Appetite inhibition classically results in defense of body weight by a reduction of energy expenditure (7,8).”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 3×
“GLP-1’s insulinotropic effects are dependent on the prevailing glucose level (10), which accounts for the relatively small insulinotropic response observed during GLP-1 infusion alone, as glucose levels tend to decline after the start of the infusion (Fig.”
BackgroundMethodSelf-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416 · cited 1×
“Any abnormal eating behavior was assessed using the Dutch Eating Behavior Questionnaire (23) and the SCOFF questionnaire (24).”
MethodGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“The postprandial nausea seen in this study may instead be accounted for by a delay in gastric emptying triggered by glucagon and GLP-1 (31,32).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“As a result, GLP-1 is capable of achieving a modest reduction in body weight (12).”
Background
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Co-infusion of GLP-1 and glucagon to human subjects resulted in decreased food intake, likely secondary to GLP-1 action, and increased energy expenditure, suggested to be driven by glucagon action [783,785].”
BackgroundSelf-citationA Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020) · Molecules · doi:10.3390/molecules25081987 · Cited by 494
“Nevertheless, several studies [50] also verified that acute co-infusion of low doses of GLP-1 and glucagon significantly reduced food intake and increased energy expenditure and this effect was achieved with peptide infused alone as well.”
BackgroundThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“The preclinical results are beginning to be corroborated by observations in non-human primates (274, 588) and clinical studies, which show that co-infusion of GLP-1 and glucagon decreases food intake (96) while increasing energy expenditure (575).”
ResultSignaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
“In humans, coadministration of GLP-1 and glucagon results in a superior reduction in food intake than either GLP-1 or glucagon alone.(557) Besides, GLP-1 can neutralize hyperglycemia caused by glucagon,(558) and polypharmacy can achieve the same reduction in food intake or increase in energy expenditure at fewer doses.”
BackgroundWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Glucagon agonism reduces also food intake [61] and increases energy expenditure [62], suggesting that it could promote WL (Fig.”
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Gut-Brain Cross-Talk in Metabolic Control
Clemmensen, C., Müller, T. D., Woods, S. C., Berthoud, H.-R., Seeley, R. J., & Tschöp, M. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.025 · Cited by 297
“Follow-up studies confirmed this phenomenon in rodent studies (Pocai et al., 2009) as well as by using co-infusion of GLP-1 and glucagon in humans (Cegla et al., 2014; Tan et al., 2013).”
BackgroundGlucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“In human volunteers, the co-administration of GLP-1 RAs and GCG RA appears to be able to reduce food intake and increase energy expenditure compared to single administration of the two drugs [160].”
BackgroundIslet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 235
“Most bariatric surgeries significantly alter circulating levels of hormones such as GLP-1 (Korner et al., 2007), glucose-dependent insulin-tropic peptide (GIP) (Näslund et al., 1998), peptide YY (PYY) (Chan et al., 2006), bile acids (Patti et al., 2009; Ryan et al., 2014), glucagon (Jørgensen et al., 2013), ghrelin (…”
BackgroundAnti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“Separately, low-dose coinfusion of GLP-1 and glucagon has been demonstrated to decrease food intake (Cegla et al., 2014) and to increase energy expenditure in humans (Tan et al., 2013).”
BackgroundGLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
“It was found that acute co-infusion of low doses of GLP-1 and native glucagon reduced food intake and increased energy expenditure to a greater extent than was achieved with either peptide infused alone [89, 90].”
BackgroundGlucagon lowers glycemia when β cells are active
Capozzi, M. E., Wait, J. B., Koech, J., Gordon, A. N., Coch, R. W., Svendsen, B., Finan, B., D’Alessio, D. A., & Campbell, J. E. (2019) · JCI Insight · doi:10.1172/jci.insight.129954 · Cited by 165
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Salem, V., Izzi‐Engbeaya, C., Coello, C., Thomas, D. B., Chambers, E. S., Comninos, A. N., Buckley, A., Win, Z., Al‐Nahhas, A., Rabiner, E. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12585 · Cited by 167
“Glucagon infusion acutely increases EE in humans [7,8], but the mechanism by which this occurs is not known.”
BackgroundResultSelf-citationRevisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases
Hædersdal, S., Andersen, A., Knop, F. K., & Vilsbøll, T. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00817-4 · Cited by 176
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Zimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A., Koliaki, C. C., & Mantzoros, C. S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 128
Glucagon – Early breakthroughs and recent discoveries
Åhrén, B. (2015) · Peptides · doi:10.1016/j.peptides.2015.03.011 · Cited by 134
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
Finan, B., Capozzi, M. E., & Campbell, J. E. (2020) · Diabetes · doi:10.2337/dbi19-0004 · Cited by 118
“A similar synergistic effect of glucagon and GLP-1 is seen for reductions in food intake in humans (70).”
BackgroundGut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 111
Behary, P., Tharakan, G., Alexiadou, K., Johnson, N., Wewer Albrechtsen, N. J., Kenkre, J., Cuenco, J., Hope, D., Anyiam, O., Choudhury, S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0449 · Cited by 110
“GLP-1, OXM, and PYY are released from the L cells of the small intestine and colon, and their postprandial secretion is augmented several-fold after RYGB (4,5).”
BackgroundMethodSelf-citationMonteiro, M. P., & Batterham, R. L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.053 · Cited by 105
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“Subanorectic doses of glucagon and GLP1 synergize to significantly reduce food intake 26 .”
Self-citationCalderón‐Garcidueñas, L., Franco-Lira, M., D’Angiulli, A., Rodríguez-Díaz, J., Blaurock-Busch, E., Busch, Y. M., Chao, C., Thompson, C., Mukherjee, P. S., Torres‐Jardón, R., et al. (2015) · Environmental Research · doi:10.1016/j.envres.2015.05.012 · Cited by 115
“Glucagon on the other hand, enhances glucose synthesis and release in the liver and suppresses appetite and causes weight loss (Cegla et al., 2014).”
BackgroundSuccessful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36
Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1116 · Cited by 101
Alba, M., Yee, J., Frustaci, M. E., Samtani, M. N., & Fleck, P. (2021) · Clinical Obesity · doi:10.1111/cob.12432 · Cited by 100
“While GCG receptor agonism has a potential for causing blood glucose elevation, this effect could be offset by simultaneous GLP-1 receptor agonism.(20-22) JNJ-64565111 contains a synthetic, modified oxyntomodulin (OXM) peptide and is the site-specific form of HMOXM25 (a GLP1/GCG dual agonist peptide) that is conjugate…”
BackgroundGong, M., Wen, S., Nguyen, T., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s232377 · Cited by 92
Tan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N. J. W., Holst, J. J., & Bloom, S. R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00469 · Cited by 88
Self-citationClemmensen, C., Finan, B., Fischer, K., Tom, R. Z., Legutko, B., Sehrer, L., Heine, D., Grassl, N., Meyer, C. W., Henderson, B., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404508 · Cited by 89
“Interest-ingly, recent studies have shown that integrating GLP-1R agonism with glucagon receptor agonism can enhance the weight-lowering properties of both entities in rodents (Day et al , 2009; Pocai et al , 2009) and humans (Cegla et al , 2014).”
Richards, P., Thornberry, N. A., & Pinto, S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101175 · Cited by 92
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 82
Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
“8 pmol/kg/min), GLP-1 + glucagon combination at the same doses, or placebo for 120 minutes we showed that there was a 13% decrease in food intake after the combination, with the individual infusions having no significant effect (67), further supporting the concept of co-agonism with these hormones.”
BackgroundSelf-citationFinan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
“, maintaining a significant reduction in food intake with little effect on plasma glucose levels; Figure 2).(81,124)”
BackgroundResultGuerrero-Hreins, E., Goldstone, A. P., Brown, R. M., & Sumithran, P. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110303 · Cited by 62
Antiepileptic drugs influences on body weight in people with epilepsy
Hamed, S. A. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.991716 · Cited by 61
“The expression and secretion of these central neuromolecules and peptides are affected by the anabolic (corticosteroids and ghrelin) and catabolic (leptin, insulin and glucagon-like peptide 1) peripheral hormones (FIGURE 1) [64,65].”
BackgroundDi Prospero, N. A., Yee, J., Frustaci, M. E., Samtani, M. N., Alba, M., & Fleck, P. (2021) · Clinical Obesity · doi:10.1111/cob.12433 · Cited by 60
“While GCGR agonism can increase blood glucose levels,(32) previous studies have indicated that this mechanism could be efficiently offset by the GLP-1R activity, but these effects did not carry over in this study.(31,33) Taken together, the increases in FPG and fasting insulin levels associated with JNJ64565111 are no…”
BackgroundCombination therapies for obesity
Camilleri, M., & Acosta, A. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0075 · Cited by 59
Irwin, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i15.1285 · Cited by 59
The effects of GLP-1 agonists on musculoskeletal health and orthopedic care
Gatto, A., Liu, K., Milan, N., & Wong, S. (2025) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-025-09978-3 · Cited by 55
Problem or solution: The strange story of glucagon
Scott, R. V., & Bloom, S. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.013 · Cited by 54
Self-citationSingh, A., Sohal, A., & Batta, A. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i48.5205 · Cited by 52
“As a result, dual agonists such as GCGR/GLP-1 RA might offer even more hepatoprotective effects due to a combination of both of these mechanisms[36].”
Ceddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 53
Knerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
The Role of Glucagon-Like Peptide-1 in Energy Homeostasis
Salehi, M., & Purnell, J. Q. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0088 · Cited by 46
Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
Scott, R., Minnion, J., Tan, T., & Bloom, S. R. (2018) · Peptides · doi:10.1016/j.peptides.2018.04.008 · Cited by 48
“Glucagon also has a dose-dependent effect on energy expenditure, with increased energy expenditure at higher doses [25,26].”
BackgroundResultSelf-citationPharmacological Support for the Treatment of Obesity—Present and Future
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 68
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44
Inhibiting or antagonizing glucagon: making progress in diabetes care
Lefèbvre, P. J., Paquot, N., & Scheen, A. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12480 · Cited by 44
“[90] reported that co-administration of glucagon and GLP-1, at doses which are individually subanorectic, significantly reduce food intake.”
BackgroundGLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
Elvert, R., Herling, A. W., Bossart, M., Weiss, T., Zhang, B., Wenski, P., Wandschneider, J., Kleutsch, S., Butty, U., Kannt, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13212 · Cited by 42
“Co-infusion of native glucagon and GLP-1 revealed that beneficial effects on food consumption, body weight and glucose control could be achieved, compared to treatment with mono-agonists.(17,18) It was further shown that resting energy expenditure was not affected by GLP-1 infusion alone, but rose significantly when h…”
BackgroundResultStructural analysis of the dual agonism at GLP-1R and GCGR
Li, Y., Zhou, Q., Dai, A., Zhao, F., Chang, R., Ying, T., Wu, B., Yang, D., Wang, M., & Cong, Z. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303696120 · Cited by 50
Purnell, J. Q., Johnson, G., Wahed, A. S., Man, C. D., Piccinini, F., Cobelli, C., Prigeon, R. L., Goodpaster, B. H., Kelley, D. E., Staten, M. A., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4553-y · Cited by 43
“Interestingly, our data are consistent with a recently demonstrated dual role for increased glucagon and GLP-1 levels in facilitating long-term weight-loss maintenance after RYGB through appetite regulation [37].”
The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease
Galsgaard, K. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124049 · Cited by 43
“Glucagon’s effect on energy expenditure and satiety may be translatable to humans, since glucagon/GLP-1 and glucagon infusions, but not the GLP-1 infusion, increased energy expenditure to a similar degree in overweight subjects without diabetes [67], and a glucagon/GLP-1 infusion decreased food intake [68].”
BackgroundNovel mechanisms involved in leptin sensitization in obesity
Pena-León, V., Pérez-Lois, R., Villalón, M. C., Prida, E., Muñoz-Moreno, D., Fernø, J., Quiñones, M., Al–Massadi, O., & Seoane, L. M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116129 · Cited by 46
Renaissance of leptin for obesity therapy
Quarta, C., Sanchez-Garrido, M. A., Tschöp, M. H., & Clemmensen, C. (2016) · Diabetologia · doi:10.1007/s00125-016-3906-7 · Cited by 41
“While it remains to be uncovered how exactly the dual agonist activating glucagon- and GLP-1 receptors alleviates leptin unresponsiveness, the antiobesity properties of concerted GLP-1R and glucagon receptor co-agonism translates to humans [61, 62], and several pharmaceutical companies are now pursuing GLP/glucagon co…”
Maciel, M. G., Beserra, B. T. S., Oliveira, F. C. B., Ribeiro, C. M., Coêlho, M. S., Neves, F. D. A. R., & Amato, A. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.034 · Cited by 40
Otten, J., Ryberg, M., Mellberg, C., Andersson, T., Chorell, E., Lindahl, B., Larsson, C., Holst, J. J., & Olsson, T. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0082 · Cited by 36
Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men
Izzi‐Engbeaya, C. N., Jones, S., Crustna, Y., Machenahalli, P. C., Papadopoulou, D., Modi, M., Panayi, C., Starikova, J., Eng, P. C., Phylactou, M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa072 · Cited by 41
“4 pmol/kg/min GLP-1 does not reduce food intake (12); therefore, the lack of a significant effect on reproductive hormone levels reported may have been due to the low dose of GLP-1 used (9).”
BackgroundMethodSelf-citationGlucagon-based therapy: Past, present and future
Patil, M., Deshmukh, N., Patel, M. V., & Sangle, G. V. (2020) · Peptides · doi:10.1016/j.peptides.2020.170296 · Cited by 37
Glucagon in type 2 diabetes: Friend or foe?
Caruso, I., Marrano, N., Biondi, G., Genchi, V. A., D'Oria, R., Sorice, G. P., Perrini, S., Cignarelli, A., Natalicchio, A., Laviola, L., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3609 · Cited by 35
Gastrointestinal hormones and their role in obesity
Choudhury, S. M., Tan, T. M., & Bloom, S. R. (2016) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000216 · Cited by 35
Self-citationCracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34
Self-citationHypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss
Hope, D. C. D., Hinds, C. E., Lopes, T., Vincent, M. L., Shrewsbury, J. V., Yu, A. T. C., Davies, I., Scott, R., Jones, B., Murphy, K. G., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100810 · Cited by 32
“However, when combined with glucagon-like peptide-1 (GLP-1) in humans, glucagon has been shown to enhance energy expenditure (EE) and reduce food intake, with preservation of glycemic neutrality in response to meals.(8,9) Several multi-agonists with GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR) activity are cur…”
BackgroundSelf-citationGogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“…advantages over GLP-1 RA alone: (a) a synergistic reduction in food intake, (b) increased energy expenditure, countering the tendency to reduce resting energy expenditure with WL, and (c) a neutral effect on glycemia, offering the potential for improved long-term glycaemic control with WL [67,71].”
BackgroundPancreatic alpha cells and glucagon secretion: Novel functions and targets in glucose homeostasis
Wendt, A., & Eliasson, L. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102199 · Cited by 37
Yang, P., Zou, H., Amso, Z., Lee, C., Huang, D., Woods, A. K., Nguyen-Tran, V. T. B., Schultz, P. G., & Shen, W. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00093 · Cited by 33
Nishizaki, H., Matsuoka, O., Kagawa, T., Kobayashi, A., Watanabe, M., & Moritoh, Y. (2021) · Diabetes · doi:10.2337/db21-0451 · Cited by 36
“In fact, glucagon has been reported to exhibit synergistic effects with GLP-1 in stimulating insulin secretion and reducing food intake in humans (28).”
BackgroundWhytock, K. L., Carnero, E. A., Vega, R. B., Tillner, J., Bock, C., Chivukula, K., Yi, F., Meyer, C., Smith, S. R., & Sparks, L. M. (2021) · Obesity · doi:10.1002/oby.23141 · Cited by 30
“Indeed, when lower doses of glucagon were infused (~10 ng/kg/min) previously, small increases in EE (~50 kcal/d) did not reach statistical significance (20).”
BackgroundJiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
“63 In obese and diabetic monkeys, chronic administration of the GLP-1/GCG dual agonist caused a 30% – 40% reduction in total energy intake and an approximately 8% reduction in body weight, an effect superior to that of the GLP-1 mono agonist liraglutide.”
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 31
No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century
Hope, D. C. D., Tan, T., & Bloom, S. R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00442 · Cited by 35
Self-citationEffects of 13-Hour Hyperglucagonemia on Energy Expenditure and Hepatic Glucose Production in Humans
Chakravarthy, M., Parsons, S., Lassman, M. E., Butterfield, K., Lee, A. Y. H., Chen, Y., Previs, S., Spond, J., Yang, S., Bock, C., et al. (2017) · Diabetes · doi:10.2337/db16-0746 · Cited by 28
“0 ng/(kg 3 min) without adverse events (4,5) but risk of nausea and vomiting at ;10 ng/(kg 3 min) (11).”
BackgroundAssessment of individual and standardized glucagon kinetics in healthy humans
LAURENTI, M. C., Vella, A. V., Adams, J. D., Wismayer, D. S., Egan, A. M., & Man, C. D. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00488.2020 · Cited by 28
Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
Αλεξιάδου, Κ., & Tan, T. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01309-9 · Cited by 27
Self-citationGlucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence
McGlone, E. R., Bloom, S. R., & Tan, T. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0365 · Cited by 30
“Acute glucagon infusion (<3 h) leads to an increase in energy expenditure in normal weight (Salem et al. 2016, Chakravarthy et al. 2017) and overweight individuals (Tan et al. 2013, Cegla et al. 2014) as measured by indirect calorimetry.”
BackgroundSelf-citationKokkinos, A. D., Tsilingiris, D., le Roux, C. W., Rubino, F., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153960 · Cited by 29
Role of enteroendocrine hormones in appetite and glycemia
Ricardo-Silgado, M. L., MCRAE, A. N., & Acosta, A. J. (2021) · Obesity Medicine · doi:10.1016/j.obmed.2021.100332 · Cited by 32
Perspectives in weight control in diabetes - survodutide
Klein, T., Augustin, R., & Hennige, A. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110779 · Cited by 25
Elvert, R., Bossart, M., Herling, A. W., Weiss, T., Zhang, B., Kannt, A., Wagner, M., Haack, T., Evers, A., Dudda, A., et al. (2018) · Endocrinology · doi:10.1210/en.2018-00399 · Cited by 24
A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity
Vega, R. B., Whytock, K. L., Gassenhuber, J., Goebel, B., Tillner, J., Agueusop, I., Truax, A. D., Yu, G., Carnero, E., Kapoor, N., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab118 · Cited by 24
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Knerr, P. J., Finan, B., Gelfanov, V. M., Pérez–Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.047 · Cited by 24
Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy
Khoo, B. C. E., & Tan, T. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0119 · Cited by 23
Self-citationYazawa, R., Ishida, M., Balavarca, Y., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15064 · Cited by 23
Current and Emerging Treatment Options in Diabetes Care
Clemmensen, C., Müller, T. D., Finan, B., Tschöp, M. H., & DiMarchi, R. D. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_7 · Cited by 23
Gray, S. M., Goonatilleke, E., Emrick, M. A., Becker, J. O., Hoofnagle, A. N., Stefanovski, D., He, W., Zhang, G., Tong, J., Campbell, J. E., et al. (2023) · Diabetes · doi:10.2337/db23-0201 · Cited by 29
Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity
Soni, H. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.08.005 · Cited by 24
Triple Agonism Based Therapies for Obesity
Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00770-z · Cited by 22
Frampton, J., Izzi‐Engbeaya, C. N., Salem, V., Murphy, K. G., Tan, T., & Chambers, E. S. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01223-y · Cited by 23
“Two studies were identified during the full-text screening phase that selected glucagon doses that were defined as sub-anorectic [45] or prevented hyperglycaemia [47].”
BackgroundInfluentialSelf-citationA new paradigm for treating obesity and diabetes mellitus
Scheen, A. J., & Paquot, N. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.3 · Cited by 24
Galsgaard, K. D., Elmelund, E., Johansen, C. D., Bomholt, A. B., Kizilkaya, H. S., Ceutz, F. R., Hunt, J. E., Kissow, H., Winther‐Sørensen, M., Sørensen, C. M., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101639 · Cited by 20
Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1
Gastaldelli, A., Gaggini, M., & DeFronzo, R. (2017) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000384 · Cited by 19
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Metadata
- Authors
- Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., Minnion, J., Cuenco, J., Ghatei, M. A., Meeran, K., Tan, T. M., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Bloom, Stephen R.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-10-13
- Volume
- 63
- Issue
- 11
- Pages
- 3711-3720
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2115939390
- Cited by
- 159
- References
- 49
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 19 · 2023: 14 · 2022: 10 · 2021: 15 · 2020: 13 · 2019: 12 · 2018: 16 · 2017: 11 · 2016: 9 · 2015: 17 · 2014: 1
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (ACF-2007-21-023, ACF-2010-21-012, ACF-2010-21-017)
- Imperial College Healthcare NHS Trust
- National Institutes of Health
- Medical Research Council (MR/J010936/1, MR/K02115X/1, MR/K023667/1, MR/J010731/1)
- Biotechnology and Biological Sciences Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- glucagon-like peptide-1, glucagon, dietary intake, appetite, obesity, weight loss, satiety hormones, energy expenditure, hyperglycemia, diabetes treatment
- MeSH terms
- Adult, Eating, Glucagon, Humans, Hyperglycemia, Male, Cross-Over Studies, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.